RBC Capital raised the firm’s price target on Insulet (PODD) to $350 from $330 and keeps an Outperform rating on the shares. The firm cites the company’s Q2 earnings beat and revenue beat along with Q3 guidance that was well above consensus with its best-in-class product offering, market access, and execution, the analyst tells investors in a research note. Insulet is attractively positioned ahead as it continues to gain market share and furthers growth in a highly underpenetrated market as its catalysts continue to play out, the firm added.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PODD:
- Insulet price target raised to $353 from $331 at Canaccord
- Insulet Corporation Reports Strong Q2 2025 Growth
- Insulet’s Earnings Call Highlights Robust Growth and Optimism
- Insulet’s Strong Financial Performance and Optimistic Outlook Justify Buy Rating
- Insulet’s Strong Market Position and Growth Potential Justify Buy Rating with Increased Price Target